Ep. 369 - ASCO advances, China innovation & U.S. science under threat

Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data for the company’s daraxonrasib, Akeso’s Harmoni-6 readout, as well as other results from the meeting. BioCentury’s analysts then argue that U.S. biotech executives and policymakers should embrace the challenges and opportunities that come with the rise of innovation in China — rather than sticking their heads in the sand. They also discuss why leaders of the U.S.’s biggest drug companies should use their influence to stop an OMB proposal that threatens the foundations of U.S. science. Plus: takeaways from BioCentury's conversation with Alkermes CEO Richard Pops on The BioCentury Show.View full story: https://www.biocentury.com/article/659629#ASCO #PancreaticCancer #BiotechInnovation #ChinaBiotech #DrugDevelopment00:00 - Introduction01:49 - ASCO: RevMed06:50 - ASCO: Akeso16:33 - China U.S. Biotech Rivalry24:15 - Science Under Threat36:29 - Richard Pops TakeawaysTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text